Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release Capsules
FDA Class II
FDA classified this recall as Class II: the product may cause health problems that are temporary or can be treated; the chance of serious harm is remote.
- Hazard
- CGMP deviations: N-nitroso-duloxetine impurity above the proposed interim limit.
- Products
-
- Duloxetine Delayed-Release Capsules
- Where it was sold
-
AZ, IN, NJ
States: Arizona, Indiana, New Jersey
- Units affected
- 3,591 bottles
- About this recall
- Duloxetine Delayed-Release Capsules, USP, 30 mg, 1,000 Capsules per bottle, Rx Only, Manufactured by: Towa Pharmaceutical Europe, S.L., Martorelles, (Barcelona), Spain. Manufactured for: Quallent Pharmaceuticals Health LLC, Grand Cayman, Cayman Islands. NDC: 82009-030-10